Travere Therapeutics (NASDAQ:TVTX) Posts Earnings Results, Misses Expectations By $0.45 EPS

Travere Therapeutics (NASDAQ:TVTX) announced its quarterly earnings data on Monday. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.45), Zacks reports. Travere Therapeutics had a negative return on equity of 152.48% and a negative net margin of 18.66%. The business had revenue of $224.56 million during the quarter, compared to the consensus estimate of $195.29 million. During the same period in the prior year, the firm earned $0.28 EPS. The business’s revenue for the quarter was up 36.2% compared to the same quarter last year.

Here are the key takeaways from Travere Therapeutics’ conference call:

• Positive Sentiment: FILSPARI U.S. net product sales rose approximately 120% year over year to $200.2 million in Q3, surpassing $200 million for the first time. Management cited strong demand, prescription conversion, and patient persistence across IgA nephropathy and the newly approved FSGS indication.
• Positive Sentiment: FSGS launch momentum was strong, with rapid conversion to paid prescriptions, expanding prescriber adoption, and payer coverage progressing well. Travere said roughly 40% of first-time FSGS prescribers in the quarter were new to FILSPARI, supporting its confidence in achieving or exceeding $3 billion in annual sales by 2033.
• Negative Sentiment: Q3 FILSPARI sales benefited by approximately $8 million from elevated specialty-pharmacy inventory, which is expected to reverse in Q4 as distributors return to normal stock levels. The company also expects higher discounts, with full-year gross-to-net deductions in the mid-20% range.
• Positive Sentiment: The pipeline advanced, with pegtibatinase HARMONY enrollment progressing toward top-line results in the second half of 2027 and civorebrutinib moving toward a U.S. IND submission by year-end. Travere also reported patent progress for FILSPARI that could extend protection in IgA nephropathy and FSGS into 2037.
• Neutral Sentiment: CEO Eric Dube plans to step down in December, with Bradley expected to join as his successor on December 1. Management characterized the transition as occurring from a position of strength, though leadership changes remain an execution consideration for investors.

Travere Therapeutics Trading Up 0.3%

Shares of NASDAQ:TVTX opened at $49.41 on Wednesday. Travere Therapeutics has a 52-week low of $22.59 and a 52-week high of $68.73. The company has a market capitalization of $4.66 billion, a P/E ratio of -38.30 and a beta of 1.11. The company has a 50-day simple moving average of $58.42 and a 200 day simple moving average of $46.67. The company has a debt-to-equity ratio of 24.58, a quick ratio of 3.99 and a current ratio of 4.05.

Insider Activity

In other Travere Therapeutics news, insider William Rote sold 112,850 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $63.33, for a total value of $7,146,790.50. Following the sale, the insider owned 98,197 shares in the company, valued at $6,218,816.01. This represents a 53.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Cline sold 50,508 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $3,148,668.72. Following the completion of the sale, the chief financial officer owned 87,508 shares in the company, valued at $5,455,248.72. This represents a 36.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,294,029 shares of company stock valued at $79,454,261. 4.44% of the stock is owned by insiders.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Quarterly revenue reached $224.56 million, up 36.2% year over year and above analyst expectations. FILSPARI net product sales were $200 million, which management said reflected continued expansion in IgAN and FSGS. Travere Therapeutics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: One valuation analysis argues TVTX could be about 34% undervalued, offering a counterpoint to concerns that the stock’s sharp rally has left it fully priced. Why Travere Therapeutics Could Be 34% Undervalued
• Neutral Sentiment: Technical coverage focused on TVTX approaching its 200-day moving average, a level investors may watch for potential support. Travere is on a crash course with its 200-day line
• Negative Sentiment: The company posted a third-quarter loss of $0.55 per share, missing analyst estimates, and swung to a loss from earnings of $0.28 per share a year earlier. The earnings shortfall offsets the encouraging revenue beat. Travere Therapeutics Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: Another article describes the shares as potentially fully priced after a roughly sevenfold run, raising the risk that valuation could limit further gains. Travere Therapeutics Stock Looks Fully Priced After Its 7x Run

Analyst Upgrades and Downgrades

TVTX has been the topic of several recent research reports. Evercore set a $78.00 price target on shares of Travere Therapeutics in a research note on Monday, August 10th. Canaccord Genuity Group increased their price objective on shares of Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Citigroup increased their price objective on shares of Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Friday, September 18th. Finally, TD Cowen lifted their target price on Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $69.50.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.